68Ga-Pentixafor PET/CT in the Localization Diagnosis of Primary Aldosteronism Concurrent Subclinical Cushing’s Syndrsome: Two Case Reports

Xin Wei,Feifei Wu,Haoyu Dong,Ying Jing,Ying Song,Hua Pang,Jing Chen,Zhipeng Du,Wenwen He,Linqiang Ma,Yue Wang,Jinbo Hu,Qifu Li,Shumin Yang
DOI: https://doi.org/10.1007/s12020-024-03865-6
2024-01-01
Endocrine
Abstract:Adrenal venous sampling (AVS) is recommended for subtyping primary aldosteronism (PA). However, in cases of PA, concurrent subclinical Cushing’s syndrome (SCS) has the potential to confound AVS results. Pentixafor, a CXC chemokine receptor type 4–specific ligand, has been reported as a promising marker to evaluate functional nature of adrenal adenomas. This study aims to investigate the clinical value of Gallium-68 Pentixafor Positron Emission Tomography–Computed Tomography (68Ga-Pentixafor PET/CT) in the localization diagnosis of patients with PA plus SCS. Two patients with a confirmed diagnosis of PA plus SCS underwent AVS and 68Ga-Pentixafor PET/CT. AVS results revealed no lateralization for both patients while 68Ga-Pentixafor PET/CT showed a unilateral adrenal nodule with increased uptake of 68Ga-Pentixafor. Unilateral adrenalectomy was performed based on the results of 68Ga-Pentixafor PET/CT. Subsequently, complete biochemical remission of autonomous aldosterone and cortisol secretion were achieved in both cases. 68Ga-Pentixafor PET/CT shows promising potential for the localization of aldosterone and cortisol co-secreting adrenal adenoma in patients with PA plus SCS.
What problem does this paper attempt to address?